Copyright
©The Author(s) 2019.
World J Gastroenterol. Oct 7, 2019; 25(37): 5687-5701
Published online Oct 7, 2019. doi: 10.3748/wjg.v25.i37.5687
Published online Oct 7, 2019. doi: 10.3748/wjg.v25.i37.5687
Table 6 Target lesion response
| Downstaging | Bridging | Total | P value | ||||
| mRECIST | n | % | n | % | n | % | < 0.011 |
| CR | 8 | 14.3 | 41 | 31.8 | 49 | 26.5 | |
| PR | 39 | 69.6 | 53 | 41.1 | 92 | 49.7 | |
| SD | 8 | 14.3 | 31 | 24 | 39 | 21.1 | |
| DP | 1 | 1.8 | 4 | 3.1 | 5 | 2.7 | |
| Objective response | > 0.05 | ||||||
| OR (CR + PR) | 47 | 83.9 | 94 | 72.9 | 141 | 76.2 | |
| Non-OR (SD + PD) | 9 | 16.1 | 35 | 27.1 | 44 | 23.8 | |
- Citation: Affonso BB, Galastri FL, da Motta Leal Filho JM, Nasser F, Falsarella PM, Cavalcante RN, de Almeida MD, Felga GEG, Valle LGM, Wolosker N. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging. World J Gastroenterol 2019; 25(37): 5687-5701
- URL: https://www.wjgnet.com/1007-9327/full/v25/i37/5687.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i37.5687